Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Conference

Sulman, Erik P, Won, Minhee, Blumenthal, Deborah T et al. (2013). Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). . JOURNAL OF CLINICAL ONCOLOGY, 31(18),

International Collaboration

cited authors

  • Sulman, Erik P; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Colman, Howard; Jenkins, Robert B; Chakravarti, Arnab; Jeraj, Robert; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Dignam, James; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Gilbert, Mark R; Mehta, Minesh P; Aldape, Kenneth D

sustainable development goals

authors

date/time interval

  • May 31, 2013 -

publication date

  • June 20, 2013

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Chicago, IL

Conference

  • 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 31

issue

  • 18